FR2686900B1 - Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant. - Google Patents

Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.

Info

Publication number
FR2686900B1
FR2686900B1 FR9201065A FR9201065A FR2686900B1 FR 2686900 B1 FR2686900 B1 FR 2686900B1 FR 9201065 A FR9201065 A FR 9201065A FR 9201065 A FR9201065 A FR 9201065A FR 2686900 B1 FR2686900 B1 FR 2686900B1
Authority
FR
France
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
granulocyte colony
novel polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9201065A
Other languages
English (en)
French (fr)
Other versions
FR2686900A1 (fr
Inventor
Patrice Yeh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Rhone Poulenc Rorer SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR9201065A priority Critical patent/FR2686900B1/fr
Application filed by Rhone Poulenc Rorer SA filed Critical Rhone Poulenc Rorer SA
Priority to FI943564A priority patent/FI943564A7/fi
Priority to EP93904130A priority patent/EP0624200A1/fr
Priority to CA002125979A priority patent/CA2125979A1/fr
Priority to PCT/FR1993/000086 priority patent/WO1993015211A1/fr
Priority to JP5512987A priority patent/JPH07503844A/ja
Priority to US08/256,938 priority patent/US5665863A/en
Publication of FR2686900A1 publication Critical patent/FR2686900A1/fr
Priority to NO942858A priority patent/NO942858L/no
Application granted granted Critical
Publication of FR2686900B1 publication Critical patent/FR2686900B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FR9201065A 1992-01-31 1992-01-31 Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant. Expired - Fee Related FR2686900B1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
FR9201065A FR2686900B1 (fr) 1992-01-31 1992-01-31 Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
EP93904130A EP0624200A1 (fr) 1992-01-31 1993-01-28 Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant
CA002125979A CA2125979A1 (fr) 1992-01-31 1993-01-28 Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant
PCT/FR1993/000086 WO1993015211A1 (fr) 1992-01-31 1993-01-28 Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant
FI943564A FI943564A7 (fi) 1992-01-31 1993-01-28 Uusia polypeptidejä, joilla on jyvässolupesäkkeitä stimuloivaa aktiivi suutta, niiden valmistus ja niitä sisältäviä farmaseuttisia koostumuks ia
JP5512987A JPH07503844A (ja) 1992-01-31 1993-01-28 顆粒球コロニー刺激活性を有する新規なポリペプチド，それらの調製およびそれらを含有する医薬組成
US08/256,938 US5665863A (en) 1992-01-31 1993-01-29 Polypeptides having granulocyte colony stimulating activity, their preparation and pharmaceutical compositions containing them
NO942858A NO942858L (no) 1992-01-31 1994-08-01 Nye polypeptider med granulocyt-koloni-stimulerende aktivitet, deres fremstilling samt farmasöytiske prepatater inneholdende polypeptidene

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9201065A FR2686900B1 (fr) 1992-01-31 1992-01-31 Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.

Publications (2)

Publication Number Publication Date
FR2686900A1 FR2686900A1 (fr) 1993-08-06
FR2686900B1 true FR2686900B1 (fr) 1995-07-21

Family

ID=9426191

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9201065A Expired - Fee Related FR2686900B1 (fr) 1992-01-31 1992-01-31 Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.

Country Status (8)

Country Link
US (1) US5665863A (enExample)
EP (1) EP0624200A1 (enExample)
JP (1) JPH07503844A (enExample)
CA (1) CA2125979A1 (enExample)
FI (1) FI943564A7 (enExample)
FR (1) FR2686900B1 (enExample)
NO (1) NO942858L (enExample)
WO (1) WO1993015211A1 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5718893A (en) * 1984-04-15 1998-02-17 Foster; Preston F. Use of G-CSF to reduce acute rejection
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5536495A (en) * 1994-04-15 1996-07-16 Foster; Preston F. Use of G-CSF to reduce acute rejection
FR2719593B1 (fr) * 1994-05-06 1996-05-31 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur préparation et composition pharmaceutique les contenant.
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
TWI242563B (en) * 1998-04-30 2005-11-01 Tanox Inc Monoclonal agonist antibodies which specifically bind to or interact with human G-CSF receptor
BR9910568A (pt) * 1998-04-30 2001-09-11 Tanox Inc Anticorpos agonistas de receptor de g-csf e processo de seleção para os mesmos
JP2002534059A (ja) * 1998-10-13 2002-10-15 ザ ユニバーシティ オブ ジョージア リサーチファウンデーション，インコーポレイティド 安定化された生物活性ペプチドおよび同定、合成および使用方法
US20030190740A1 (en) * 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
ATE269716T1 (de) 2000-02-29 2004-07-15 Pfizer Prod Inc Stabilisierter granulozyten-kolonie- stimulierender faktor
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
US6926898B2 (en) * 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
SI1724284T1 (sl) * 2000-12-07 2009-12-31 Lilly Co Eli Glp-1 fuzijski proteini
US20050054051A1 (en) * 2001-04-12 2005-03-10 Human Genome Sciences, Inc. Albumin fusion proteins
US20060084794A1 (en) * 2001-04-12 2006-04-20 Human Genome Sciences, Inc. Albumin fusion proteins
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
US20050244931A1 (en) * 2001-04-12 2005-11-03 Human Genome Sciences, Inc. Albumin fusion proteins
WO2003030821A2 (en) * 2001-10-05 2003-04-17 Human Genome Sciences, Inc. Albumin fusion proteins
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
AU2003210806A1 (en) * 2002-03-05 2003-09-22 Eli Lilly And Company Heterologous g-csf fusion proteins
EP2426139B1 (en) 2002-08-27 2014-10-01 Biokine Therapeutics Ltd. CXCR4 antagonist and use thereof
WO2005034877A2 (en) * 2003-10-10 2005-04-21 University Of Southern California G-csf transferrin fusion proteins
US7220407B2 (en) 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
CN102816241B (zh) * 2004-02-09 2015-07-22 人类基因科学公司 清蛋白融合蛋白
WO2005121174A2 (en) * 2004-06-04 2005-12-22 Five Prime Therapeutics, Inc. Novel g-csf polypeptides, polynucleotides, modulators thereof, and methods of use
IL164942A0 (en) * 2004-10-31 2005-12-18 Yeda Res & Dev The use of a protease or a protease inhibitor for the manufacture of medicaments
AU2005306894B2 (en) 2004-11-05 2011-11-24 Northwestern University Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders
EP1816201A1 (en) * 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
EP3011961B1 (en) 2006-12-21 2020-11-11 Biokine Therapeutics LTD. 4f-benzoyl-tn14003 for the mobilisation of hematopoietic progenitor cells in view of transplantation
EP2318029B1 (en) 2008-07-23 2017-11-01 Ambrx, Inc. Modified bovine g-csf polypeptides and their uses
BRPI1004940A2 (pt) * 2009-01-16 2018-06-19 Teva Pharma composição farmacêutica
EP2396023A2 (en) 2009-02-11 2011-12-21 Yeda Research and Development Co. Ltd. Short beta-defensin-derived peptides
US9427456B2 (en) 2009-06-14 2016-08-30 Biokine Therapeutics Ltd. Peptide therapy for increasing platelet levels
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
EP2737905B1 (en) 2011-07-25 2019-09-11 Generon (Shanghai) Corporation Ltd. Use of g-csf dimer in preparation of medicament for treatment of neurodegenerative diseases
WO2013160895A1 (en) 2012-04-24 2013-10-31 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer
US20140271538A1 (en) 2013-03-15 2014-09-18 Teva Pharmaceutical Industries Ltd. Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor for the Prevention of Neutropenia in Pediatric Patients
GB201316592D0 (en) * 2013-09-18 2013-10-30 Levicept Ltd Fusion protein
GB201412748D0 (en) * 2014-07-17 2014-09-03 Levicept Ltd Therapeutic use of P75NTR neurotrophin binding protein
MX2017016844A (es) 2015-07-16 2018-08-15 Biokine Therapeutics Ltd Composiciones y procedimientos para tratar cancer.
US10654912B2 (en) 2015-09-08 2020-05-19 Jcr Pharmaceuticals Co., Ltd. Human serum albumin mutant
CA3014530A1 (en) 2016-02-23 2017-08-31 Biolinerx Ltd. Methods of treating acute myeloid leukemia
EP3431508A4 (en) 2016-03-14 2019-08-14 JCR Pharmaceuticals Co., Ltd. SERUM ALBUMIN-20-K-GROWTH HORMONE FUSION PROTEIN
US10866963B2 (en) 2017-12-28 2020-12-15 Dropbox, Inc. File system authentication

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR871067B (en) * 1986-07-18 1987-11-19 Chugai Pharmaceutical Co Ltd Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor
FR2649991B2 (fr) * 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5298243A (en) * 1988-10-20 1994-03-29 Denki Kagaku Kogyo Kabushiki Kaisha Colony stimulating factor-gelatin conjugate
EP0401384B1 (en) * 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
EP0395918A3 (en) * 1989-04-13 1991-10-23 Vascular Laboratory, Inc. Plasminogen activator complex of pure pro-urokinase covalently bound by a disulfide bridge to human serum albumin
GB8909916D0 (en) * 1989-04-29 1989-06-14 Delta Biotechnology Ltd Polypeptides
EP0489116B1 (en) * 1989-08-22 1994-04-06 Immunex Corporation Fusion proteins comprising gm-csf and il-3

Also Published As

Publication number Publication date
FR2686900A1 (fr) 1993-08-06
WO1993015211A1 (fr) 1993-08-05
FI943564L (fi) 1994-07-29
FI943564A0 (fi) 1994-07-29
FI943564A7 (fi) 1994-07-29
EP0624200A1 (fr) 1994-11-17
US5665863A (en) 1997-09-09
NO942858D0 (enExample) 1994-08-01
NO942858L (no) 1994-08-01
CA2125979A1 (fr) 1993-08-05
JPH07503844A (ja) 1995-04-27

Similar Documents

Publication Publication Date Title
FR2742751B1 (fr) Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
FI943564A0 (fi) Uusia polypeptidejä, joilla on jyvässolupesäkkeitä stimuloivaa aktiivisuutta, niiden valmistus ja niitä sisältäviä farmaseuttisia koostumuksia
DZ2009A1 (fr) Nouveaux taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
EP1449921A3 (fr) Nouveaux polypeptides biologiquement actifs, leur préparation et composition pharmaceutique les contenant
DZ2979A1 (fr) Composés nouveaux modulateurs de chimiokine ccr5, et compositions pharmaceutiques les contenant.
FR2727411B1 (fr) Nouveaux derives de perhydroisoindole, leur preparation et les compositions pharmaceutiques qui les contiennent
DZ2745A1 (fr) BicycloÄ2.2.1Üheptanes nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26490A1 (fr) Derives de tetrahydroisoquinoleine nouveaux, procedes pour leur preparation et compositions pharmaceutiques les contenant.
MA26513A1 (fr) Derives du bis-indole ayant une activite antimetastasique, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2582309B1 (fr) Nouveaux derives du morphinane et de la morphine, leur preparation, leur application comme medicaments et les compositions pharmaceutiques les contenant
FR2732968B1 (fr) Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2796380B3 (fr) Nouveaux derives d'aminothiazoles, leur preparation et les compositions pharmaceutiques les contenant
MA26552A1 (fr) Derives d'isoquinoleine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2687151B1 (fr) Nouveaux derives de la baccatine iii et de la desacetyl-10 baccatine iii, leur preparation et les compositions pharmaceutiques qui les contiennent.
FR2703995B1 (fr) 5-acylamino 1,2,4-thiadiazoles, leur preparation et compositions pharmaceutiques en contenant.
FR2745814B1 (fr) Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2740453B1 (fr) Melanges peptidiques, leur preparation et compositions cosmetiques les contenant
FR2712288B1 (fr) Nouveaux taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
FR2719593B1 (fr) Nouveaux polypeptides biologiquement actifs, leur préparation et composition pharmaceutique les contenant.
FR2732342B1 (fr) Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2721023B1 (fr) Nouveaux Taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
FR2772761B1 (fr) Nouveaux derives de n-phenylamide et n-pyridylamide, leur procede de preparation et compositions pharmaceutiques les contenant
FR2807043B1 (fr) Composition pharmaceutique contenant des oligosaccharides, les nouveaux oligosaccharides et leur preparation
FR2791980B1 (fr) Pyrido-thieno-diazepines, leur procede de preparation, et les compositions pharmaceutiques les contenant
FR2631829B1 (fr) Exopolysaccharides fongiques ayant une activite immunostimulante, leur procede d'obtention et composition therapeutique les contenant

Legal Events

Date Code Title Description
ST Notification of lapse